ArticleFrontiers in medicine2026
Association between systemic blood pressure control and outcomes of Conbercept treatment for macular edema secondary to retinal vein occlusion.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the association between the level of systemic blood pressure (BP) control and the clinical outcomes of intravitreal Conbercept for macular edema (ME) secondary to retinal vein occlusion (RVO). Methods: We conducted a retrospective study of hypertensive patients who were treated between January and June 2025 at the Second People's Hospital of Jinan for ME secondary to RVO. All patients received a 0.05 mL (10 mg/mL) intravitreal Conbercept injection and concurrent medical management for hypertension. Patients were stratified into three groups depending on if their BP were under control (Group A), partially under control (Group M), or out of control (Group Z) based on their BP during the follow-up over 1 month. Results: The study included 76 patients (36 males, 40 females) with a mean age of 63.11 ± 10.10 years. The number of patients in each group was as follows: Group A, Conclusion: Systemic BP control is associated with the short-term efficacy of Conbercept for ME secondary to RVO, and patients with well-controlled BP achieve superior visual and anatomical outcomes. This underscores the importance of co-managing systemic hypertension.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.